Geode Capital Management LLC raised its stake in shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT – Free Report) by 41.2% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 427,651 shares of the company’s stock after purchasing an additional 124,787 shares during the period. Geode Capital Management LLC owned 0.95% of Checkpoint Therapeutics worth $958,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors have also made changes to their positions in CKPT. B. Riley Wealth Advisors Inc. raised its position in shares of Checkpoint Therapeutics by 366.3% during the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 229,200 shares of the company’s stock valued at $493,000 after buying an additional 180,050 shares in the last quarter. PVG Asset Management Corp purchased a new stake in shares of Checkpoint Therapeutics during the 2nd quarter valued at about $295,000. Wealth Enhancement Advisory Services LLC raised its position in shares of Checkpoint Therapeutics by 160.0% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 130,000 shares of the company’s stock valued at $291,000 after buying an additional 80,000 shares in the last quarter. Walleye Capital LLC purchased a new stake in shares of Checkpoint Therapeutics during the 3rd quarter valued at about $148,000. Finally, State Street Corp raised its position in shares of Checkpoint Therapeutics by 32.2% during the 3rd quarter. State Street Corp now owns 94,424 shares of the company’s stock valued at $212,000 after buying an additional 23,000 shares in the last quarter. Institutional investors own 22.00% of the company’s stock.
Checkpoint Therapeutics Price Performance
Checkpoint Therapeutics stock opened at $3.16 on Friday. Checkpoint Therapeutics, Inc. has a 1-year low of $1.38 and a 1-year high of $4.50. The firm has a market capitalization of $154.31 million, a P/E ratio of -1.72 and a beta of 1.36. The company’s 50-day moving average is $3.65 and its 200 day moving average is $2.86.
Insider Buying and Selling
In other Checkpoint Therapeutics news, CFO William Garrett Gray sold 268,432 shares of the company’s stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $4.01, for a total value of $1,076,412.32. Following the transaction, the chief financial officer now directly owns 1,032,754 shares in the company, valued at $4,141,343.54. This represents a 20.63 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO James F. Oliviero III sold 220,230 shares of the company’s stock in a transaction dated Thursday, December 19th. The stock was sold at an average price of $3.38, for a total transaction of $744,377.40. Following the completion of the transaction, the chief executive officer now owns 3,194,583 shares in the company, valued at $10,797,690.54. This represents a 6.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.10% of the stock is currently owned by corporate insiders.
Wall Street Analyst Weigh In
Several analysts have recently issued reports on CKPT shares. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Checkpoint Therapeutics in a research report on Monday, December 16th. Lake Street Capital upped their target price on shares of Checkpoint Therapeutics from $4.00 to $7.00 and gave the company a “buy” rating in a research report on Monday, December 16th.
Read Our Latest Research Report on Checkpoint Therapeutics
About Checkpoint Therapeutics
Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.
Recommended Stories
- Five stocks we like better than Checkpoint Therapeutics
- How to Evaluate a Stock Before Buying
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- What is a Stock Market Index and How Do You Use Them?
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.